Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 3—March 2011
Synopsis

Q Fever in France, 1985–2009

Diane Frankel, Hervé Richet, Aurélie Renvoisé, and Didier RaoultComments to Author 
Author affiliations: Author affiliation: Université de la Méditerranée, Marseille, France

Main Article

Table 1

Serum samples tested for Q fever, by year, France*

Year No. positive/
no. tested (%) No. positive
Acute disease Chronic disease
1985 239/2,290 (10.4) 22 8
1986 518/3,464 (15.0) 37 8
1987 767/4,361 (17.6) 52 12
1988 706/3,403 (20.7) 49 12
1989 1,316/4,258 (30.9) 40 18
1990 1,621/4,720 (34.3) 92 22
1991 1,737/5,028 (34.5) 112 20
1992 2,011/5,249 (38.3) 89 29
1993 1,815/7,020 (25.9) 76 26
1994 1,472/7,222 (20.4) 102 24
1995 1,359/6,171 (22.0) 73 34
1996 1,326/7,101 (18.7) 116 28
1997 1,683/7,050 (23.9) 70 35
1998 1,420/7,340 (19.3) 140 37
1999 1,537/8,296 (18.5) 199 32
2000 1,460/8,444 (17.3) 135 32
2001 1,589/8,974 (17.7) 167 38
2002 2,029/10,639 (19.1) 224 55
2003 2,094/10,588 (19.8) 242 52
2004 2,544/10,742 (23.7) 360 70
2005 2,514/10,597 23.7) 199 100
2006 2,010/7,891 (25.5) 266 237
2007 1,700/5,522 (30.8) 244 278
2008 2,073/10,981 (18.9) 256 263
2009 1,933/12,443 (15.5) 361 205
Total 39,472/179,794 (21.9) 3,723 1,675

*Acute disease, phase II (avirulent bacteria) immunoglobulin (Ig) G titer >200 and phase II IgM titer >50; chronic disease, phase I (virulent bacteria) IgG titer >800.

Main Article

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external